| Autor: |
Timothy Mant, Timothy V Olah, Michael Stepanavage, Johanna Wittreich, Haiyung Cheng, Barry J. Gertz, Mark Edwards, David G. Sciberras, Polvino William J |
| Rok vydání: |
1997 |
| Předmět: |
|
| Zdroj: |
British Journal of Clinical Pharmacology. 43:49-54 |
| ISSN: |
0306-5251 |
| DOI: |
10.1111/j.1365-2125.1997.tb00137.x |
| Popis: |
Aim We evaluated the pharmacokinetics and pharmacodynamics of oral MK-462 in comparison with oral sumatriptan in healthy male volunteers. Methods Sixteen healthy male volunteers were studied in a rising, single dose, alternating panel design with eight subjects per panel. Matching placebo was administered to two of eight study subjects at each dose level of MK-462 in a randomized, double-blind fashion. Results MK-462 was rapidly absorbed with a median tmax of 1.3 h (range 1–3 h) vs a tmax for sumatriptan of 2.5 h (range 1–4 h, P < 0.001). Administration of either MK-462 or sumatriptan produced maximal mean elevations of 5–10 mmHg in systolic and diastolic blood pressures without effect on heart rate; the changes occurred sooner following MK-462, consistent with more rapid absorption. Both MK-462 and sumatriptan provoked mild increases in serum growth hormone without any effect on serum prolactin concentrations. The most commonly reported symptom following MK-462 was drowsiness. Conclusions These results indicate that the novel 5-HT1D agonist, MK-462, is rapidly absorbed following oral administration and warrants further investigation of its utility in the treatment of acute migraine. |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
Plný text